Abstract
A neutropenic patient with acute myeloid leukaemia experienced a breakthrough infection of Trichosporon asahii during posaconazole treatment. After treatment was changed to a combination therapy with voriconazole and liposomal amphotericin B, the infection resolved. Posaconazole works effectively as an antifungal prophylaxis and salvage therapy in rare invasive fungal infections. This case however illustrates that breakthrough infections with T. asahii may occur during posaconazole treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Paphitou NI, Ostrosky-Zeichner L, Paetznick V, Rodriguez JR, Chen E, Rex JH (2002) In vitro antifungal susceptibility of Trichosporon species. Anitmicrob Agents Chemother 46:1144–1146
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al (2007) Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2–12
Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D’Antonio D, Piccolomini R (2006) Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob Agents Chemother 50:3269–3276
Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, et al (1992) Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 15:781–787
Spanakis E, Aperis G, Mylonakis E (2006) New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 43:1060–1068
Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, et al (2004) Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum, and determinants of outcome. Scand J Infect Dis 36:564–569
Krcmery V Jr, Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z, et al (1999) Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during intraconazole. Support Care Cancer 7:39–43
Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, et al (2002) Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microb Infect Dis 21:892–896
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rieger, C., Geiger, S., Herold, T. et al. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 26, 843–845 (2007). https://doi.org/10.1007/s10096-007-0366-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-007-0366-5